-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90

Benzinga·12/17/2025 13:02:39
Listen to the news
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $75 to $90.